Literature DB >> 23506091

The 14bp-deletion allele in the HLA-G gene confers susceptibility to the development of hepatocellular carcinoma in the Brazilian population.

A C Teixeira1, C T Mendes-Junior, F F Souza, L A Marano, N H S Deghaide, S C Ferreira, E D Mente, A K Sankarankutty, J Elias-Junior, O Castro-e-Silva, E A Donadi, A L C Martinelli.   

Abstract

Human leukocyte antigen-G (HLA-G) is a nonclassical HLA class I molecule involved in tumor escape mechanisms. Considering that the HLA-G 14bp insertion/deletion polymorphism is located at the 3' untranslated region (3'UTR) in exon 8, and since it has been associated with the magnitude of HLA-G production, we studied the association of 14bp insertion/deletion polymorphism with the risk of developing hepatocellular carcinoma (HCC). A total of 109 HCC patients followed at the University Hospital, Faculty of Medicine of Ribeirão Preto, São Paulo, Brazil, and 202 healthy controls from the same geographic area were genotyped for the 14bp insertion/deletion polymorphism using polymerase chain reaction (PCR) and polyacrylamide gel electrophoresis. Compared to controls, the frequency of the 14bp deletion allele was overrepresented in HCC patients (65% versus 56%, respectively, P = 0.0326). The 14bp deletion conferred an odds ratio (OR) of 1.46 [95% confidence interval (CI): 1.04-2.05]. Similarly, the deletion/deletion genotype was marginally overrepresented in HCC patients (45% versus 35% in controls, P = 0.0871), conferring an OR of 1.54 (95% CI: 0.96-2.48). The frequencies of the deletion/insertion or insertion/insertion genotypes observed in patients were not statistically different from those observed in controls (P > 0.05). Our results suggest that the 14bp-deletion allele in HLA-G gene is associated with HCC susceptibility in a Brazilian population.
© 2013 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23506091     DOI: 10.1111/tan.12097

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  7 in total

1.  The association between the HLA-G 14-bp insertion/deletion polymorphism and type 1 diabetes.

Authors:  H P V Silva; M A G Ururahy; K S C Souza; M B Loureiro; Y M C Oliveira; G H M Oliveira; A D Luchessi; K T C Carvalho; J C O C Freitas; E A Donadi; R D C Hirata; M G Almeida; R F Arrais; M H Hirata; A A Rezende
Journal:  Genes Immun       Date:  2015-10-22       Impact factor: 2.676

2.  Genetic polymorphism in HLA-G 3'UTR 14-bp ins/del and risk of cancer: a meta-analysis of case-control study.

Authors:  Tao Li; Haohai Huang; Dan Liao; Huahuang Ling; Bingguang Su; Maode Cai
Journal:  Mol Genet Genomics       Date:  2015-01-09       Impact factor: 3.291

Review 3.  Inhibition of host immune response in colorectal cancer: human leukocyte antigen-G and beyond.

Authors:  Marica Garziera; Giuseppe Toffoli
Journal:  World J Gastroenterol       Date:  2014-04-14       Impact factor: 5.742

Review 4.  The Role of HLA-G Molecule and HLA-G Gene Polymorphisms in Tumors, Viral Hepatitis, and Parasitic Diseases.

Authors:  Fabrício C Dias; Erick C Castelli; Cristhianna V A Collares; Philippe Moreau; Eduardo A Donadi
Journal:  Front Immunol       Date:  2015-02-02       Impact factor: 7.561

5.  Genetic variation in the HLA-G 3'UTR 14-bp insertion/deletion and the associated cancer risk: evidence from 25 case-control studies.

Authors:  You Jiang; Jun Lu; Yue-E Wu; Xin Zhao; Liang Li
Journal:  Biosci Rep       Date:  2019-05-10       Impact factor: 3.840

6.  Meta-analysis of HLA-G 14bp insertion/deletion polymorphism and soluble HLA-G revealed an association with digestive cancers initiation and prognosis.

Authors:  Sabrine Dhouioui; Nadia Boujelbene; Hadda-Imene Ouzari; Kalthoum Tizaoui; Inès Zidi
Journal:  Heliyon       Date:  2022-07-19

7.  Human leukocyte antigen-G expression and polymorphisms promote cancer development and guide cancer diagnosis/treatment.

Authors:  Yanwen Zhang; Shuwen Yu; Yali Han; Yunshan Wang; Yuping Sun
Journal:  Oncol Lett       Date:  2017-11-14       Impact factor: 2.967

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.